The IPO provides a massive cash infusion for a clinical-stage biotech, reducing near-term dilution risk and funding pipeline development. Watch for the Regeneron partnership details and any early clinical data readouts that could drive further upside.
Price Chart
Executive Summary
Parabilis Medicines priced its upsized IPO of 33.5M shares at $20.00/share, expecting gross proceeds of $670M, plus a concurrent private placement to Regeneron for ~$75M. The IPO is a major capital event for a clinical-stage biotech, providing substantial cash runway to advance its Helicon platform.
Key Financial Metrics
Key Facts
- Upsized IPO of 33,500,000 shares at $20.00 per share, expected gross proceeds of $670 million.
- Concurrent private placement of 4,166,666 shares at $18.00 per share to Regeneron Pharmaceuticals for ~$75 million.
- Underwriters have a 30-day option to purchase an additional 5,025,000 shares.
- Trading on Nasdaq under ticker PBLS expected to begin June 10, 2026; closing expected June 11, 2026.
- Lead underwriters: Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities.
Financial Impact
Total gross proceeds of $670M from IPO plus ~$75M from private placement = ~$745M in new capital.
Risk Factors
- Clinical-stage company with no approved products; pipeline risk is high.
- Dilution from the IPO and potential full exercise of the underwriters' option (additional 5M shares).
- Forward-looking statements subject to customary closing conditions and market volatility.
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3309413 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 3d ago | Press Release | $24.79 | awaiting T+60 | — | $26.99 (+8.85%) |
Oct 19, 2026 8d ago | Press Release | $25.35 | awaiting T+60 | — | $26.99 (+6.45%) |
Sep 15, 2026 5w ago | 8-K | $36.88 | awaiting T+60 | — | $26.99 (−26.83%) |
Sep 2, 2026 7w ago | 8-K | $40.75 | awaiting T+60 | — | $26.99 (−33.78%) |
Aug 13, 2026 10w ago | 8-K | $35.67 | awaiting T+60 | — | $26.99 (−24.35%) |
Aug 13, 2026 10w ago | Press Release | $35.67 | awaiting T+60 | — | $26.99 (−24.35%) |
Jul 22, 2026 13w ago | Insider Buy | $32.81 $22.75 | ▼ −30.66% | ▼ −34.31% | $26.99 (−17.75%) |
Jun 29, 2026 17w ago | Insider Cluster | $29.19 $33.31 | ▲ +14.11% | ▲ +10.50% | $26.99 (−7.55%) |
Jun 16, 2026 18w ago | Insider Cluster | $26.03 $36.16 | ▲ +38.92% | ▲ +36.23% | $26.99 (+3.67%) |
Jun 15, 2026 19w ago | Insider Cluster | $26.59 $36.88 | ▲ +38.70% | ▲ +36.84% | $26.99 (+1.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers